Companion Diagnostic Antibody for CA6 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing drugs for therapeutic use in patient populations is challenging due to difficulties in establishing drug interactions with intended molecular targets, determining target relevance, and identifying optimal dosing, particularly in cancer treatment where molecular targets like CA6 are overexpressed.
Innovation Solution
A companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody DS6 is developed for PET bio-imaging to detect and quantify the tumor-associated MUC1-sialoglycotope CA6, facilitating patient stratification and monitoring treatment response by identifying patients with high CA6 expression who may respond to huDS6-DM4 antibody-drug conjugate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional drug development approaches are used without companion diagnostics, then drug development process is simpler, but ability to establish drug interactions with intended molecular targets and identify optimal dosing is insufficient
Solution Approach 1:
The invention segments the drug development process by introducing a companion diagnostic component that operates independently alongside the therapeutic drug development. This allows parallel evaluation of drug candidates with specific molecular targets (CA6), enabling precise measurement of drug-target interactions without complicating the overall drug development workflow. The diagnostic can be administered separately and evaluated independently, providing clear data on target engagement and dosing optimization.
2Reliability
If companion diagnostic is introduced to evaluate drug interactions, then measurement precision of target engagement is improved, but development time and resource requirements increase
Solution Approach 1:
The companion diagnostic is designed to be administered prior to or concurrently with the therapeutic drug, allowing preliminary assessment of CA6 target expression and engagement. This preliminary action provides reliable data on target engagement early in the treatment process, enabling timely decisions about dosing optimization and patient selection without significantly extending the overall development timeline.
3Loss of information
If imaging techniques are used for in vivo detection, then ability to assess molecular target interaction is improved, but radiation exposure and imaging time increase
Solution Approach 1:
The invention utilizes PET imaging parameters optimized for detecting the specific CA6-targeted drug interaction. By selecting appropriate radiotracers and imaging time points that match the pharmacokinetics of the therapeutic antibody, the system maximizes information retrieval about therapeutic efficacy while minimizing radiation exposure. The imaging protocol is tailored to capture the essential data needed for dosing decisions without unnecessary prolonged exposure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The companion diagnostic allows for early evaluation of therapeutic efficacy, patient stratification, and monitoring of treatment response, reducing drug development attrition and ensuring effective medicine delivery by identifying patients with high CA6 expression who benefit from huDS6-DM4 treatment.
Implementation Method 1
The antibody-like binding protein further comprises a chelator, wherein the antibody-like binding protein is conjugated to a suitable chelator for coupling to the bio-imaging tracer
Data Source
AI summary
The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6.